Unknown

Dataset Information

0

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.


ABSTRACT: Phosphatidylinositol-3-kinase p110? serves as a central integration point for signaling from cell surface receptors known to promote malignant B-cell proliferation and survival. This provides a rationale for the development of small molecule inhibitors that selectively target p110? as a treatment approach for patients with B-cell malignancies. We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective and potent p110? small molecule inhibitor (half-maximal effective concentration [EC(50)] = 8nM). Using tumor cell lines and primary patient samples representing multiple B-cell malignancies, we have demonstrated that constitutive phosphatidylinositol-3-kinase pathway activation is p110?-dependent. CAL-101 blocked constitutive phosphatidylinositol-3-kinase signaling, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and caspase cleavage and an induction of apoptosis. These effects have been observed across a broad range of immature and mature B-cell malignancies, thereby providing a rationale for the ongoing clinical evaluation of CAL-101.

SUBMITTER: Lannutti BJ 

PROVIDER: S-EPMC3694505 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

Lannutti Brian J BJ   Meadows Sarah A SA   Herman Sarah E M SE   Kashishian Adam A   Steiner Bart B   Johnson Amy J AJ   Byrd John C JC   Tyner Jeffrey W JW   Loriaux Marc M MM   Deininger Mike M   Druker Brian J BJ   Puri Kamal D KD   Ulrich Roger G RG   Giese Neill A NA  

Blood 20101019 2


Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from cell surface receptors known to promote malignant B-cell proliferation and survival. This provides a rationale for the development of small molecule inhibitors that selectively target p110δ as a treatment approach for patients with B-cell malignancies. We thus identified 5-fluoro-3-phenyl-2-[(S)-1-(9H-purin-6-ylamino)-propyl]-3H-quinazolin-4-one (CAL-101), a highly selective and potent p110δ small molecu  ...[more]

Similar Datasets

| S-EPMC4916562 | biostudies-literature
| S-EPMC6826943 | biostudies-literature
| S-EPMC8636012 | biostudies-literature
| S-EPMC10433971 | biostudies-literature
| S-EPMC7727518 | biostudies-literature
| S-EPMC3540743 | biostudies-literature
2016-12-22 | GSE89868 | GEO
| S-EPMC7784594 | biostudies-literature
| S-EPMC6728602 | biostudies-literature
| S-EPMC2797439 | biostudies-literature